Medical science is undergoing a genomic revolution. In coming years, insights from human genomic research will increasingly influence all aspects of infectious diseases, ranging from fundamental laboratory research and clinical care to epidemiology and global health. Infectious disease specialists unfamiliar with genomic methods and computational techniques may shy away from publications that involve human genomics analyses. In this article, we discuss selected aspects of study design and statistical analysis in this area, emphasizing important pitfalls that may compromise the validity of some studies. Our goal is to provide the infectious diseases specialist with information that will aid in the critical evaluation of publications that include human genomic analyses.
All fields of medical science are being affected by the revolution in human genomics, as evidenced by the growing number of journal articles that include human genetic data. During the 12 months ending June 2006, human genetics was the focus of at least 10 research studies published in volume 193 of The Journal of Infectious Diseases [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Unfortunately, infectious disease specialists who are unfamiliar with genomic study design and interpretation may shy away from such publications. Even the vocabulary can be confusing; for example, the words genetic and genomic are often used interchangeably, yet there are subtle differences. Genomic analyses generally encompass very large numbers of genes, whereas genetic analyses involve one or very few variants. Additionally, genomic analyses may also investigate genomic structure, coding and noncoding regions, control and regulatory elements, etc. In this Perspective article, we discuss issues relevant to the design, analysis, and interpretation of genetic and genomic association studies, particularly as they relate to infectious diseases. For simplicity, we will preferentially use the term genomics, rather than genetics, throughout this article.
Elucidating genomic and environmental factors that predict or help explain pathogenesis, clinical manifestations, and responses to vaccines and medications holds great promise for infectious disease disciplines that range from basic laboratory research to epidemiology. The ability to make clinical predictions based on host and environmental factors is a foundation of preventive medicine and the rising paradigm of personalized medicine. However, for most complex diseases, it is extremely difficult to develop accurate predictive models based on genomics. This is because, unlike diseases with Mendelian inheritance (e.g., sickle cell anemia) that are largely attributable to a single genetic factor and follow simple patterns of inheritance, complex diseases, such as drugresponse phenotypes, may involve interactions among multiple genetic and/or environmental factors [11] [12] [13] [14] .
There are 2 broad types of study design that may be used to identify relationships between human genomic variants and phenotypes of interest-linkage analysis and association analysis [15] . Linkage analysis uses genotype and phenotype data from multiple biologically related family members to determine whether a chromosomal region is preferentially inherited by offspring with the trait of interest. Linkage analysis relies on the fact that, as the causative gene segregates through a kindred, other nearby markers on the same chromosome tend to segregate together (are in linkage) with the causative gene, due to the lack of recombination in that region. Although linkage analysis is a very powerful approach, it has practical limitations for the study of infectious diseases. Most important, because it requires kindreds with multiple affected and unaffected relatives, infectious disease questions are less often amenable to this approach. In addition, although current linkage analysis methods can detect a strong independent main effect that tracks to a single chromosomal region, they have difficulty when multiple genetic factors on different chromosomes interact to confer the phenotype [16] .
Association analysis describes the use of family-based, case-control, or cohort data to statistically relate genetic factors to the phenotype of interest. Because association analysis directly examines the effect of a candidate locus, rather than an effect that is diffused across large regions of chromosomes, its greatest applicability is in fine localization and identification of causative loci. Unlike linkage mapping, association mapping is usually readily applicable to infectious disease questions [17] .
It is important to consider the definition of a causative locus in the context of infectious disease studies. Although the disease itself is necessarily caused by an infectious pathogen, the phenotype under investigation is hypothesized to be mitigated by either host or pathogen genetics. For the purposes of the present article, we use the word causative to refer to the genetic locus/loci that influence susceptibility, alters the clinical severity of a disease, etc.
DESIGNING ASSOCIATION ANALYSES
Arguably, the most important aspect of any association analysis is the careful selection of cases that have the phenotype of interest-and of appropriate controls that lack that phenotype. Complex phenotypes that comprise many different traits and symptoms may be difficult to dichotomize in this manner. This problem is compounded if statistical methods require dichotomous outcomes, forcing each individual to be either a case or control subject, with no intermediate options.
Misclassification of cases and controls will decrease power to detect true genetic associations or, less commonly, may lead to false associations [18] . Genomic studies can also focus on quantitative traits, with similar study designs but different analytical methods. A detailed review of the analytical approaches designed for such phenotypic end points is beyond the scope of the present Perspective article.
After cases and controls have been classified, a strategy to relate phenotypic data to human genomics must be selected. Of the several types of variants dispersed within the human genome, single-nucleotide polymorphisms (SNPs) are most often used in association analyses and are most amenable to large-scale high-throughput assays. A SNP is a genomic locus where 2 or more alternate base pairs occur in the population, at a minor allele frequency of у1%. SNPs are the most frequent genomic variants, occurring approximately once every several hundred base pairs. Compared with other molecular markers, SNPs exhibit very low mutation rates [19] . Although we emphasize SNPs in this Perspective article, other variants, such as insertions and deletions, are also appropriate for many of the analyses described.
When one chooses which SNPs to include in an association analysis, one may use either a direct or an indirect strategy. Increasingly, many studies combine both strategies. For direct association analysis, the investigator studies candidate genes for which a plausible hypothesis can be stated to relate gene to phenotype. The investigator compiles a list of candidate genes, on the basis of considerations that may include expert knowledge of underlying biological characteristics or drug-disposition pathways, results from previous linkage or association analyses, expression array analyses, and cross-species comparative genomics. Once a list of candidate genes has been assembled, a subset of SNPs to be assayed is chosen. This often involves a compromise between exhaustively interrogating every SNP and practical limits imposed by available funding for assay work. For direct association analysis, preference is often given to SNPs that are most likely to be functional, such as nonsynonymous SNPs (i.e., SNPs that change protein sequence) or promoter SNPs (i.e., SNPs that may alter gene expression). Polymorphisms that previous studies have found to be associated with a phenotype are often included as well. Investigators may also preferentially include SNPs that are frequent in the population and SNPs at intron/exon boundaries that may affect splicing. Database tools often used to help choose which SNPs to assay include PANTHER [20, 21] , SNPEffect [22, 23] , SNPSeek (http://snp .wustl.edu/SNPseek/index.cgi), dbSNP (http://www.ncbi.nih.gov/SNP), and HapMap (http://www.hapmap.org).
Indirect association analyses rely on the fact that, over many human generations, recombination rarely occurs between multiple SNPs that are in close proximity on a chromosome. As a result, SNPs within a relatively small region of a chromosome may exist as a block that is in linkage disequilibrium (LD), which describes the nonrandom association of alleles at multiple genetic loci. Blocks of such statistically associated SNPs are called haplotype blocks (also called LD blocks) [24] [25] [26] . Because these multiple SNPs are inherited as a unit, knowing the base at any 1 SNP in the block may allow identification of all other SNPs in that block. Variants that efficiently distinguish between LD blocks are called tagging SNPs, because they "tag" other SNPs in the block [27] ; this concept is illustrated in figure 1 . The goal of indirect association analysis is to find the LD block (containing the causative polymorphism) that is most strongly associated with the outcome of interest. If an LD block contains the causative SNP, then the frequency of the tagging SNP for that block will differ between cases and controls.
Indirect association analyses can utilize 2 different strategies. The first focuses on candidate genes or candidate genomic regions. The investigator selects SNPs to span the region of interest, to include at least 1 tagging SNP from each LD block. The emphasis is on spacing between SNPs rather than on likely SNP functionality. Several methods and software applications facilitate the selection of tagging SNPs [28] [29] [30] [31] . An alternative method for indirect association studies relies on wholegenome association studies. Until recently, association analysis involving the whole genome was prohibitive because of both cost and throughput, because at least several hundred thousand SNPs per individual must be assayed to allow detection of variants in proximity of most, if not all, potential causal variants. However, as of the writing of this Perspective article, genotyping technologies are available that can evaluate ∼500,000 or more SNPs for !$1000 US/individual [32] . As a result, SNPs that span most LD blocks across the genome can be evaluated. Computational analysis of data sets generated from wholegenome association studies remains a major challenge, as discussed below.
An important caveat for indirect association analysis is that LD blocks differ by geographic region of ancestry [33] [34] [35] . If tagging SNPs are chosen on the basis of LD patterns reported for populations represented in the International HapMap Project (i.e., whites in Utah, Han Chinese, Japanese, and Yoruba Nigerians) [28] , investigators must consider whether these groups represent their study population. Tagging SNPs must be selected for each population being studied, because LD patterns vary greatly between human populations, and incorrect tagging will decrease the statistical power of any association study.
Each association strategy has pros and cons. Results of direct association analyses tend to be most readily understood and may be testable at the functional level but have limited potential to uncover novel biology. Indirect association analyses are relatively unconstrained by the limits of previous knowledge but may not meet some of the underlying assumptions required for their success, such as strong LD with the causative SNPs. Indirect association analysis based on whole-genome association studies has enormous potential to uncover novel associations but still depends on the ability to effectively tag functional SNPs, and data analysis is a computational challenge [32, 36] .
RELATING GENOMIC ASSAY RESULTS TO PHENOTYPE
The goal of any genomic association study is to determine which variants are associated with the outcome of interest, whether through direct causality or indirect linkage disequilibrium. Traditional statistical methods such as x 2 test, Fisher's exact test, and regression analysis are well suited for detection of associations between a single genetic variant and the outcome of interest.
An alternative statistical approach relies on haplotypes. It has been argued that exploring associations by use of multiple tightly linked SNPs (haplotypes) within candidate gene regions may be more powerful than studying individual SNPs [37, 38] . In case-control studies, haplotypes are typically estimated, rather than precisely assayed, because parental genotypes are usually unavailable and because extensive sequencing of individual DNA strands is usually prohibitively expensive in terms of resources. Different methods for estimation of haplotypes can yield different results [39, 40] . An advantage of a haplotype approach is that it may narrow the candidate genomic region so that one may eventually identify the causative variant. Representative software packages for estimation of haplotypes include Haploview [41] and PowerMarker [42] .
When complex phenotypes are being studied, not only individual SNPs or LD blocks (i.e., main effects) but also multilocus interactions, either between multiple SNPs or between genomic and environment factors, must be considered [11, [43] [44] [45] [46] . It is hypothesized that complex phenotypes may depend on the simultaneous presence of multiple SNPs dispersed across the genome. Many traditional statistical methods are suitable for identification of main effects, but, as the number of genomic loci assayed increases, the number of possible multilocus interactions grows exponentially. This "curse of dimensionality" [47] limits the usefulness of traditional parametric techniques, increasing type I errors and generating parameter estimates with large SEs [48, 49] .
Traditional logistic regression modeling approaches have limited ability to handle large numbers of factors, especially if there are no main effects [50] . This limitation can increase type II errors and decrease power [51] . Newer methods that may better detect interactions in high-dimensional analyses include set association [52] , combinatorial partitioning [53] , multifactor dimensionality reduction [54] , focused interaction-testing framework [55] , and neural networks [56, 57] . Such approaches are not without limitations, however, because results from such analyses may be difficult to interpret, and spurious associations may still arise from chance alone, as discussed below.
Perhaps the greatest pitfall in genomic association analysis is the risk of false discovery due to multiple testing. As the number of loci increases, so does the number of statistical tests typically performed. This problem may become overwhelming as the field embraces genomewide studies. For example, x 2 testing of a whole genome-association data set of 500,000 SNPs may yield 25,000 chance associations at and 50 at . Traditional P ! .05 P ! .0001 approaches such as the Bonferroni correction adjust for type I error but are extremely conservative [58] and may reject true associations. For genomic studies, these correction procedures may demand unrealistically small significance levels and often ignore issues of between-test dependence [58] due to linkage between markers. It may be more appropriate to correct for multiple testing with the false-discovery rate (FDR) method, which considers the expected number of false rejections divided by the total number of rejections. The FDR of a set of predictions is the expected percentage of false predictions within that set of predictions [59] . The FDR method is less conservative than the Bonferroni correction [59] but still may be too conservative for very large numbers of variables. Permutation testing is also used to decrease the impact of multiple comparisons, through empirical estimates of significance. With extremely large data sets, however, permutation testing may exceed available computational capacity.
With large-scale genomic analyses, a major challenge involves discerning the biological relevance of statistically significant results. It is often assumed that statistically significant gene-gene interactions must be explained by an interesting underlying biological phenomenon. Although this may be true in many cases, statistically significant-interaction models do not necessarily correspond to explanatory biological models. Statistical significance does not assure that mechanistic significance will readily be found [14, 60] . To utilize a popular quip, it is important to remember that "correlation is not necessarily causation."
CAVEATS FOR ASSOCIATION STUDIES
Case-control genomic association analysis is a powerful and practical way to study complex phenotypes, but there are potential pitfalls [61, 62] . In addition to the risk of false discovery discussed above, an assumption underlying most association studies is the "common-disease commonvariant" hypothesis [63] . This hypothesis presumes that the phenotype of interest is due to genetic loci with 1 (or very few) common variant(s) [63] . In this situation, association analysis is a powerful way to detect and model the genetic architecture of common, complex diseases. However, if phenotypes are the consequence of many rare genetic variants, association analyses will not be very useful, because competing signals from many rare alleles will tend to cancel each other out [64, 65] .
Genotyping error is more problematic for case-control association analyses than for family-based analyses, because kindred data can be quality checked for genotyping error based on Mendelian inconsistencies. Tests for Hardy-Weinberg equilibrium (HWE) are typically used to suggest genotyping errors in association studies. For example, if a minor (min) allele frequency is 10% and a major (maj) allele frequency is 90%, one would expect approximately 81% maj/maj, 18% maj/ min, and 1% min/min in the population. Marked deviation from such expected frequencies must be explained. Assumptions for HWE testing include random assortment of alleles from generation to generation, an infinitely large population, and a lack of evolutionary pressure. Gross deviation from HWE suggests genotyping error or population admixture [66] , but deviation may also indicate disease associations. For example, the hemoglobin S variant in Africa deviates from HWE because heterozygotes are relatively tolerant of Plasmodium falciparum infection whereas homozygotes die at a young age. It is therefore important to assess for HWE in cases separately from that in controls [67] .
Population stratification (the presence, within the study population, of multiple subpopulations with different allelic frequencies) is problematic for any population-based (as opposed to family-based) studies, such as case-control or observational cohort designs, because it can lead to false associations [68] . This is most often influenced by population ancestry. Unlike clinical trials, which may strive for diversity to increase generalizability, genetic association analyses are most powerful when they involve relatively homogeneous populations to avoid confounding by population differences. If cases and controls are drawn from somewhat different populations, genotype differences may reflect population origin rather than disease status. Matching cases and controls on the basis of ancestral origin minimizes this problem, but confounding variables may still be missed, especially because selfreported race may be unreliable. Some investigators include sets of random, unlinked genomic markers to assess for population stratification, which can be adjusted for in the analyses. Analytical methods used for this purpose include genomic control [69] and structured association [68, 70] . It is ideal, although rarely feasible, to have sample sizes sufficiently large to allow separate case-control analyses in each population.
For the reasons noted above, every association that is first identified remains only tentative until it is validated by separate studies [71] . Many association analyses published in prominent journals fail subsequent efforts to replicate the association [72] . This happens because the initial association may have been spurious due to population stratification, genotyping error, or chance [73, 74] . Small sample size in replication data sets may also prevent validation, because the sample size used for validation may actually have to exceed that used in the initial study. Even slight between-study differences in phenotype definition may prevent replication [75] . The initial association may be population specific because of other environmental or genomic factors, including gene-gene and gene-environment interactions. To avoid filling journal pages with false associations, the editors of at least 1 human genomics journal recently published standards for the design and reporting of association studies [61] . Although it is ideal to publish only associations that have been replicated in multiple studies, investigators may not have access to multiple independent data sets. The inclusion of appropriate disclaimers in the reporting of tentative associations pending validation may allow the larger scientific community to consider such preliminary data-and perhaps to perform independent validation studies.
HUMAN GENOMICS AND INFECTIOUS DISEASES-THE HIV EXAMPLE
The epidemiology, pathogenesis, and/or therapeutics of virtually every infectious disease are almost certainly influenced by human genomics, an influence that is exemplified by HIV-1. Individuals who are homozygous for a 32-bp deletion in the chemokine-receptor gene CCR5 are highly resistant to becoming infected with HIV-1 [76, 77] . This CCR5 "D32" variant became established in Europe centuries ago, likely under selective pressure from some other pathogen (perhaps Yersinia pestis [78] or smallpox [79] ). Additional human genetic variants reported to influence HIV-1 transmission, viral replication, and/ or disease progression include those of the major histocompatibility complex (MHC) genes [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] , as well as other variants, in the chemokine receptors CCR5 [90] [91] [92] [93] [94] , CCR2 [91] , and CX3CR1 [95] , the chemokine-receptor ligands CCL5 (RANTES) [96] , CCL2 (MCP1) [97, 98] , CCL3L1 (MIP1aP) [99] , and CXCL12 (SDF-1) [100] , the cytokine IL10 [101] , a killer immunoglobulin-receptor (KIR) gene [102] , and APOBEC3G [103] . Just as HIV evolves within the human body to escape selective pressure from MHC genes, the human genome is also under selective pressure from microbes. In sub-Saharan Africa, where HIV is highly endemic, genetic factors that delay HIV disease progression (e.g., certain HLA types) will likely become somewhat enriched in the population, whereas those which promote rapid progression to AIDS will decline.
Since 1987, at least 20 antiretroviral compounds have been approved for clinical use. Numerous associations between human genetic variants and antiretroviraltreatment responses and/or pharmacokinetics have been reported [104] . Associations that have been replicated in multiple studies include those between (1) abacavir-hypersensitivity reaction and HLA-B*5701 [105, 106] ; (2) efavirenz and nelfinavir pharmacokinetics and the CYP2B6 516GrT [107] [108] [109] and CYP2C19 681GrA [108, 110] polymorphisms, respectively; (3) indinavir-and atazanavirinduced hyperbilirubinemia and a UGT1A1 polymorphism [111, 112] ; and (4) nucleoside analogue-associated lipoatrophy and a TNF-a polymorphism [113, 114] . Pharmacogenomic assays of both human and viral genomes may ultimately be used to determine when therapy should be initiated, with which drugs, and at what doses. The aforementioned associations between HIV infection and its therapy highlight the potential relevance that human genomics has for all infectious diseases.
CONCLUSIONS
The ability to rapidly characterize human genomic variants, complemented by newer computational approaches, is having an increasing impact on many infectious disease disciplines. This makes ours a particularly exciting time for infectious disease practitioners and researchers alike. Infectious disease specialists who embrace the young and rapidly maturing field of human genomics will share most fully in this joyous explosion of discovery.
